Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period

Trial Profile

Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2018

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms STEP 4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 08 Aug 2018 According to a Novo Nordisk media release, all four STEP trials are expected to be completed in 2020.
    • 07 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 25 May 2018 Planned End Date changed from 4 Feb 2020 to 23 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top